Literature DB >> 15989465

Enfuvirtide is active against HIV type 1 group O.

Eva Poveda1, Pablo Barreiro, Berta Rodés, Vincent Soriano.   

Abstract

A high diversity within the HR1/HR2 regions of viral gp41 and one natural change (N42D) within the 36-45 aa domain in HIV-1 group O in comparison with HIV-1 group M isolates have led us to suspect that enfuvirtide (ENF) should not be active against HIV-1 group O. We analyzed in vitro and in vivo the antiviral activity of ENF against HIV-1 group O isolates. The IC50 at baseline was 0.15 +/- 0.028 microg/ml in a clinically derived virus specimen. After initiating treatment with ENF, a significant decline in plasma HIV-RNA and CD4 gain was noticed in one patient. Therefore, individuals with HIV-1 group O strains might benefit from ENF therapy.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15989465     DOI： 10.1089/aid.2005.21.583

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN： 0889-2229            Impact factor:   2.205


  5 in total

1.  Baseline genotypic and phenotypic susceptibilities of HIV-1 group O to enfuvirtide.

Authors:  Agnès Depatureaux; Charlotte Charpentier; Gilles Collin; Marie Leoz; Diane Descamps; Aurélia Vessière; Florence Damond; Dominique Rousset; Françoise Brun-Vézinet; Jean-Christophe Plantier
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

2.  HIV-1 Group O Genotypes and Phenotypes: Relationship to Fitness and Susceptibility to Antiretroviral Drugs.

Authors:  Denis M Tebit; Hamish Patel; Annette Ratcliff; Elodie Alessandri; Joseph Liu; Crystal Carpenter; Jean-Christophe Plantier; Eric J Arts
Journal:  AIDS Res Hum Retroviruses       Date:  2016-03-16       Impact factor: 2.205

Review 3.  Non-M variants of human immunodeficiency virus type 1.

Authors:  Thomas Mourez; François Simon; Jean-Christophe Plantier
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

4.  Divergent evolution in reverse transcriptase (RT) of HIV-1 group O and M lineages: impact on structure, fitness, and sensitivity to nonnucleoside RT inhibitors.

Authors:  Denis M Tebit; Michael Lobritz; Matthew Lalonde; Taina Immonen; Kamlendra Singh; Stefanos Sarafianos; Ottmar Herchenröder; Hans-Georg Kräusslich; Eric J Arts
Journal:  J Virol       Date:  2010-07-14       Impact factor: 5.103

Review 5.  [HIV entry into the cells--mechanisms and therapeutic possibilities].

Authors:  Verónica Briz; Eva Poveda; Vicente Soriano
Journal:  Med Clin (Barc)       Date:  2006-03-11       Impact factor: 1.725
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.